ZATA PHARMACEUTICALS, INC.
Selective pathogen inactivators (ZPI) based on polyamine scaffolds for treating convalescent plasma and blood products to eliminate pathogens while preserving therapeutic proteins
- Sector
- Biotech
- Headquarters
- Worcester, MA
- Total capital
- $21M
- Federal grants
- $8.4M
- 9 awards · 2015–2021
- Rank in peer group#69 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $12.6M
- 1 award · Health and Human S
- Rank in Biotech#55 of 4373
- Granted patents
- 5
- 12 pending · first 2019
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Federal contractHealth and Human S · Development And Maintenance Of Fda-argos 2 Universal Closed Systems For Pathogen Reduction In Donated Whole Blood Units$12.6M
- Federal grantHealth and Human S · Phase I · Highly Selective Pathogen Inactivators For Treatment of Convalescent Transfusion Plasma$718K
- Federal grantHealth and Human S · Phase II · A Closed System For Pathogen Reduction Of Red Blood Cells For Transfusion$1.2M
- Federal grantHealth and Human S · Phase II · A Closed System For Pathogen Reduction Of Red Blood Cells For Transfusion$2.2M
- Federal grantHealth and Human S · Phase II · A Closed System For Pathogen Reduction Of Red Blood Cells For Transfusion$780K
- Federal grantHealth and Human S · Phase I · New-Generation of Fluorescently-Labeled Charge-Neutralized Oligonucleotides as Probes for the Detection and Quantification of MicroRNAs and Oligonucleotide-Based Therapeutics in Biological Samples$402K
- Federal grantHealth and Human S · Phase II · Self-neutralizing Oligonucleotides With Enhanced Cellular Uptake$588K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Self Neutralizing Oligonucleotides With Enhanced Cellular Uptake$1.4M
- Federal grantHealth and Human S · Phase II · Self-neutralizing Oligonucleotides With Enhanced Cellular Uptake$796K
- Federal grantHealth and Human S · Phase I · Aziridinyl Groups Containing Polyamines As Anti-pathogen Device For Blood Products Intended For Transfusion$403K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#69 · top 13%
- Granted patents#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 5 granted of 17- GrantedDetection Method for Natural and Modified Small Nucleic AcidsUSPTOUS 12,297,225
- GrantedPhosphoramidite Synthones For The Synthesis Of Self-neutralizing Oligonucleotide CompoundsUSPTOUS 11,566,042
- GrantedAziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using The SameUSPTOUS 10,738,005
Show all 17 patent records
- Detection Method for Natural and Modified Small Nucleic AcidsMay 13, 2025 · US 12,297,225Granted
- Phosphoramidite Synthones For The Synthesis Of Self-neutralizing Oligonucleotide CompoundsJan 31, 2023 · US 11,566,042Granted
- Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using The SameAug 11, 2020 · US 10,738,005Granted
- Phosphoramidite Synthones For The Synthesis Of Self-neutralizing Oligonucleotide CompoundsJul 28, 2020 · US 10,723,755Granted
- Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using The SameJan 8, 2019 · US 10,173,976Granted
- Inactivation Modalities For Aziridinyl Based Pathogen Inactivators And Methods ThereofApplication 62711241Pending
- Phosphoramidite Synthones For The Synthesis Of Self-neutralizing Oligonucleotide CompoundsApplication PCTUS2015061343Pending
- Phosphoramidite Synthons For The Synthesis Of Self-Neutralizing Oligotherapy CompoundsApplication 62081316Pending
- Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Comprising The SameApplication PCTUS2014065367Pending
- Novel Synthetic Dinucleoside Polyphosphate Analogs And Their Use As New Therapeutic And/or Diagnostic ModalitiesApplication PCTUS2009064114Pending
- New Modalities For Treatment Of Drug-resistant Tuberculosis And Other DiseasesApplication PCTUS2009056470Pending
- Methods And Compositions For Oral, Sublingual Or Buccal Administration Of Diadenosine Tetraphosphate AnalogsApplication PCTUS2024061940Pending
- Methods and Compositions for Oral, Sublingual or Buccal Administration of Diadenosine Tetraphosphate AnalogsApplication 19601804Pending
- Methods and Compositions for Oral, Sublingual or Buccal Administration of Diadenosine Tetraphosphate AnalogsApplication 63615557Pending
- Detection Method For Natural And Modified Small Nucleic AcidsApplication PCTUS2019058078Pending
- Method For Pathogens, Microorganisms, And Parasites InactivationApplication PCTUS2019043675Pending
- Detection Method For Natural And Modified Small Nucleic AcidsApplication 62750952Pending
Related companies, and why
- HDT BIO CORPSimilar federal contract value in Biotech · $14.5M in contracts
- ENALARE THERAPEUTICS INCSimilar federal contract value in Biotech · $13M in contracts
- INIMMUNE CORPSimilar federal contract value in Biotech · $12.8M in contracts
- INOVIO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12M in contracts
- Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts
- Codagenix Inc.Similar federal contract value in Biotech · $11.2M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .